Characterisation of genotype-molecular phenotype interactions to provide a platform for genetically validated drug discovery and development in NAFLD

基因型-分子表型相互作用的表征，为 NAFLD 的基因验证药物发现和开发提供平台

• 批准号: MR/W004224/1
• 负责人: Stephen Atkinson
• 金额: $ 37.6万
• 依托单位: Imperial College London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FW004224%2F1
• 关键词: Characterisation; genotype; molecular; phenotype; interactions

Liver disease caused by excess fat in the liver is increasingly common and can lead to liver cirrhosis, cancer and death. There are currently no drug treatments available for the condition. Studies have identified common genetic changes which increase the chance of developing fatty liver though it is unclear how they do this. Understanding the link between genetics and disease provides an opportunity to develop new and effective drugs. In this project GlaxoSmithKline will partner with Imperial College London to use state-of-the-art technology to carefully examine levels of different genes in the liver samples from patients with fatty liver disease. These data will be used to understand how gene variants cause disease, how genes may be targeted by new drugs to treat disease and in which patients they may be most effective.

由肝脏中过量脂肪引起的肝脏疾病越来越常见，可导致肝硬化，癌症和死亡。目前没有药物治疗这种疾病。研究已经确定了常见的遗传变化，这些变化会增加患脂肪肝的机会，尽管目前还不清楚它们是如何做到这一点的。了解遗传学和疾病之间的联系为开发新的有效药物提供了机会。在这个项目中，葛兰素史克将与伦敦帝国理工学院伦敦合作，使用最先进的技术仔细检查脂肪肝患者肝脏样本中不同基因的水平。这些数据将用于了解基因变异如何导致疾病，新药如何靶向基因治疗疾病，以及它们在哪些患者中可能最有效。